# Arginine Therapy for Sickle Cell Disease Pain

> **NCT02536170** · PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 108 (actual)

## Conditions studied

- Sickle Cell Disease
- Vaso-occlusive Pain Episode

## Interventions

- **DRUG:** L-arginine
- **DRUG:** L-arginine Loading Dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02536170
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2021-02-21
- **Final completion:** 2021-02-21
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2023-09-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536170, "Arginine Therapy for Sickle Cell Disease Pain". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02536170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*